

《肝癌放射治療共識》

一、治療範圍

1. 肝腫瘤
2. 栓塞肝門靜脈

二、治療劑量 / 次數 (依正常肝臟劑量調整)

▲常規治療：

- 總劑量：30-66Gy
- 次數：10-33 次

▲立體定位高劑量分次治療

1. 總劑量：40-60Gy
2. 治療次數：3-5 次

▲質子放射治療

1. 分次劑量：72.6-76 GyE
2. 治療次數：20-22 次

三、治療方式：

使用立體順型與強度調控放射治療技術，包含弧形及螺旋放射規畫，可考慮搭配影像導引治療，治療選擇可使用同步照射高與低危險部位的方式或先給予整個照射部位部份劑量照射後，再針對高危險部位加強劑量。

四、參考文獻：

1. NCCN clinical practice guidelines in oncology-Hepatobiliary cancers. Version 3.2024.
2. Lee HL, et al. Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma

- unsuitable for transarterial chemoembolization. *Ther Adv Med Oncol.* 2019 , Vol 11: 1-13.
3. L.A. Dawson et al. NRG Oncology/RTOG 0438: A Phase 1 Trial of Highly Conformal Radiation Therapy for Liver Metastases. *Practical Radiation Oncology* 2019, 9, e386-393.
 4. Bush DA, et al. Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis *Int J Radiat Oncol Biol Phys.* 2016; 95: 477-482.
 5. Nitin Ohri, et al. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. *J Natl Cancer Inst.* 2016 Jul 4; 108(9).
 6. Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C, et al. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). *J Cancer Res Clin Oncol.* 2015 Jul 1;141(7):1301-9.
 7. Chen SW, Lin LC, Kuo YC, et al. Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys.* 2014 Apr 1;88(5):1041-7.
 8. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RKS, et al. Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma. *JCO.* 2013 May 1;31(13):1631-9.
 9. Cardenes HR, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. *Clin Transl Oncol* 2010; 12: 218-225.
 10. Tse RV, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *J Clin Oncol* 2008; 26: 657-664.
 11. Kim DY, et al. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. *Cancer,* 2005; 103 (11) : 2419-26.
 12. QUANTEC
 13. Mizumoto M, et al. Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols. *Int J Radiat Oncol Biol Phys.* 2011; 81:1039-45.
 14. Fukumitsu N, et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular

- carcinoma. Int J Radiat Oncol Biol Phys. 2009; 74:831-6.
15. Mizumoto M, et al. Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. Int J Radiat Oncol Biol Phys. 2008; 71:462-7.
16. Kawasima M, et al. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol. 2005; 23:1839-46.
17. Hong TS, Wo JY, Yeap BY, et al. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2016;34(5):460-468.
18. Bhangoo RS, Mullikin TC, Ashman JB, et al. Intensity Modulated Proton Therapy for Hepatocellular Carcinoma: Initial Clinical Experience. Adv Radiat Oncol. 2021;6(4):100675.